VADS REACH (GORTEC 2017-01) A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Paris
Sein Adjuvant IMPASSION 030 - BIG16-05/WO39391 A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030) Paris
Sein métastatique RH+ EMERALD ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL Paris, Saint-Cloud
Sein Adjuvant NATALEE (CLEE011O12301C) A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negartive Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE) Paris, Saint-Cloud JEAN-YVES PIERGA, JEAN-YVES PIERGA
Sein métastatique RH+ TROPICS 02 (IMMU132-09) Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus;Treatment of Physician's Choice (TPC) in subjects with Hormonal;Receptor-Positive (HR+) Human Epidermal Growth Factor;Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC);who have failed at least two prior chemotherapy regimens Paris
VADS TrilynX (Debio 1143-SCCHN-301) A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in;combination with platinum-based chemotherapy and standard fractionation intensitymodulated;radiotherapy in patients with locally advanced squamous cell carcinoma of;the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
Sein PRAVAPREV 01 A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer Paris YOULIA KIROVA